Sepsis and the Lung Host Response

Seminars in Respiratory and Critical Care Medicine

Volumn 25, Issue 1, 2004, Pages 85-93

  Frevert, Charles W ^a,b   Martin, Thomas R ^a,b  

^a VA Puget Sound   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Innate immunity; Pulmonary host defenses; Sepsis

Indexed keywords

CAUSE OF DEATH; CRITICAL ILLNESS; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFLAMMATION; LUNG; LUNG INJURY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEPSIS;

EID: 1542333721     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-822308     Document Type: Review

References (134)

1. Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. JAMA 1995;274:968-974
2. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310
3. Pinner RW, Teutsch SM, Simonsen L, et al. Trends in infectious diseases mortality in the United States. JAMA 1996;275:189-193
4. Simonsen L, Conn LA, Pinner RW, Teutsch S. Trends in infectious disease hospitalizations in the United States, 1980-1994. Arch Intern Med 1998;158:1923-1928
5. McBean M, Rajamani S. Increasing rates of hospitalization due to septicemia in the US elderly population, 1986-1997. J Infect Dis 2001;183:596-603
6. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. Chest 1992;101:1644-1655
7. Bone RC. Why sepsis trials fail. JAMA 1996;276:565-566
8. Goldie AS, Fearon KC, Ross JA, et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 1995;274:172-177
9. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997;112:235-243
10. Nelson S. A question of balance. Am J Respir Crit Care Med 1999;159(5 Pt 1):1365-1367
11. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001;163:316-321
12. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-150
13. Sibille Y, Reynolds HY. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 1990;141:471-501
14. Standiford TJ, Kunkel SL, Greenberger MJ, Laichalk LL, Strieter RM. Expression and regulation of chemokines in bacterial pneumonia. J Leukoc Biol 1996;59:24-28
15. Zhang P, Summer WR, Bagby GJ, Nelson S. Innate immunity and pulmonary host defense. Immunol Rev 2000;173:39-51
16. Gordon SB, Read RC. Macrophage defences against respiratory tract infections. Br Med Bull 2002;61:45-61
17. Hensler T, Hecker H, Heeg K, et al. Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun 1997;65:2283-2291
18. Hensler T, Heidecke CD, Hecker H, et al. Increased susceptibility to postoperative sepsis in patients with impaired monocyte IL-12 production. J Immunol 1998;161:2655-2659
19. van der Poll T, de Wall Malefyt R, Coyle SM, Lowry SF. Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis 1997;175:118-122
20. Ferguson NR, Galley HF, Webster NR. T helper cell subset ratios in patients with severe sepsis. Intensive Care Med 1999;25:106-109
21. Zimmer S, Pollard V, Marshall GD, et al. Effects of endotoxin on the Th1/Th2 response in humans. J Burn Care Rehabil 1996;17(6 Pt 1):491-496
22. Lauw FN, ten Hove T, Dekkers PE, et al. Reduced Th1, but not Th2, cytokine production by lymphocytes after in vivo exposure of healthy subjects to endotoxin. Infect Immun 2000;68:1014-1018
23. Olszyna DP, Pajkrt D, van Deventer SJ, van der Poll T. Effect of interleukin 10 on the release of the CXC chemokines growth related oncogene GRO-alpha and epithelial cell-derived neutrophil activating peptide (ENA)-78 during human endotoxemia. Immunol Lett 2001;78:41-44
24. Olszyna DP, Pajkrt D, Lauw FN, van Deventer SJ, van Der Poll T. Interleukin 10 inhibits the release of CC chemokines during human endotoxemia. J Infect Dis 2000;181:613-620
25. Pajkrt D, Camoglio L, Buul T, et al. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. J Immunol 1997;158:3971-3977
26. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216
27. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000;406:782-787
28. West MA, Heagy W. Endotoxin tolerance: a review. Crit Care Med 2002;30(suppl 1):S64-S73
29. Dobrovolskaia MA, Vogel SN. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect 2002;4:903-914
30. Munoz C, Carlet J, Fitting C, et al. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991;88:1747-1754
31. Volk HD, Thieme M, Heym S, et al. Alterations in function and phenotype of monocytes from patients with septic disease: predictive value and new therapeutic strategies. Behring Inst Mitt 1991;88:208-215
32. Wilson CS, Seatter SC, Rodriguez JL, et al. In vivo endotoxin tolerance: impaired LPS-stimulated TNF release of monocytes from patients with sepsis, but not SIRS. J Surg Res 1997;69:101-106
33. Docke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat Med 1997;3:678-681
34. Wolk K, Docke WD, von Baehr V, Volk HD, Sabat R. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 2000;96:218-223
35. Adib-Conquy M, Adrie C, Moine P, et al. NF-kappaB expression in mononudear cells of patients with sepsis resembles that observed in lipopolysaccharide tolerance. Am J Respir Crit Care Med 2000;162:1877-1883
36. Sugawara S, Nemoto E, Tada H, et al. Proteolysis of human monocyte CD14 by cysteine proteinases (gingipains) from Porphyromonas gingivalis leading to lipopolysaccharide hyporesponsiveness. J Immunol 2000;165:411-418
37. Randow F, Syrbe U, Meisel C, et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med 1995;181:1887-1892
38. Park DR, Skerrett SJ. IL-10 enhances the growth of Legionella pneumophila in human mononuclear phagocytes and reverses the protective effect of IFN-gamma: differential responses of blood monocytes and alveolar macrophages. J Immunol 1996;157:2528-2538
39. Raychaudhuri B, Fisher CJ, Farver CF, et al. Interleukin 10 (IL-10)-mediated inhibition of inflammatory cytokine production by human alveolar macrophages. Cytokine 2000;12:1348-1355
40. Cummings CJ, Martin TR, Frevert CW, et al. Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis. J Immunol 1999;162:2341-2346
41. Tavares-Murta BM, Zaparoli M, Ferreira RB, et al. Failure of neutrophil chemotactic function in septic patients. Crit Care Med 2002;30:1056-1061
42. Skoutelis AT, Kaleridis V, Athanassiou GM, et al. Neutrophil deformability in patients with sepsis, septic shock, and adult respiratory distress syndrome. Crit Care Med 2000;28:2355-2359
43. Schultz MJ, Olszyna DP, de Jonge E, et al. Reduced ex vivo chemokine production by polymorphonuclear cells after in vivo exposure of normal humans to endotoxin. J Infect Dis 2000;182:1264-1267
44. Ahmed NA, McGill S, Yee J, et al. Mechanisms for the diminished neutrophil exudation to secondary inflammatory sites in infected patients with a systemic inflammatory response (sepsis). Crit Care Med 1999;27:2459-2468
45. Laichalk LL, Danforth JM, Standiford TJ. Interleukin-10 inhibits neutrophil phagocytic and bactericidal activity. FEMS Immunol Med Microbiol 1996;15:181-187
46. Wright JR, Borron P, Brinker KG, Folz RJ. Surfactant protein A: regulation of innate and adaptive immune responses in lung inflammation. Am J Respir Cell Mol Biol 2001;24:513-517
47. Korfhagen TR. Surfactant protein A (SP-A)-mediated bacterial clearance: SP-A and cystic fibrosis. Am J Respir Cell Mol Biol 2001;25:668-672
48. Crouch E, Wright JR. Surfactant proteins A and D and pulmonary host defense. Annu Rev Physiol 2001;63:521-554
49. Tobias PS, Ulevitch RJ. Lipopolysaccharide binding protein and CD14 in LPS dependent macrophage activation. Immunobiology 1993;187:227-232
50. Raymondos K, Leuwer M, Haslam PL, et al. Compositional, structural, and functional alterations in pulmonary surfactant in surgical patients after the early onset of systemic inflammatory response syndrome or sepsis. Crit Care Med 1999;27:82-89
51. Greene KE, Wright JR, Steinberg KP, et al. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 1999;160:1843-1850
52. Cheng IW, Ware LB, Greene KE, et al. Prognostic value of surfactant proteins A and D in patients with acute lung injury. Crit Care Med 2003;31:20-27
53. Wurfel MM, Radella F II, Ruzinski JT, et al. Bronchoalveolar lavage fluid from patients with acute respiratory distress syndrome facilitates bacterial lipopolysaccharide recognition: role for lipopolysaccharide-binding protein. Am J Respir Crit Care Med 2003;167:A760
54. Reddy RC, Chen GH, Tekchandani PK, Standiford TJ. Sepsis-induced immunosuppression: from bad to worse. Immunol Res 2001;24:273-287
55. van der Poll T, Marchant A, Buurman WA, et al. Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol 1995;155:5397-5401
56. van der Poll T, Jansen PM, Montegut WJ, et al. Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. J Immunol 1997;158:1971-1975
57. van der Poll T, Marchant A, Keogh CV, Goldman M, Lowry SF. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996;174:994-1000
58. Greenberger MJ, Strieter RM, Kunkel SL, et al. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995;155:722-729
59. Steinhauser ML, Hogaboam CM, Kunkel SL, et al. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 1999;162:392-399
60. Reddy RC, Chen GH, Newstead MW, et al. Alveolar macrophage deactivation in murine septic peritonitis: role of interleukin 10. Infect Immun 2001;69:1394-1401
61. Kurahashi K, Kajikawa O, Sawa T, et al. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest 1999;104:743-750
62. Sewnath ME, Olszyna DP, Birjmohun R, et al. IL-10-deficient mice demonstrate multiple organ failure and increased mortality during Escherichia coli peritonitis despite an accelerated bacterial clearance. J Immunol 2001;166:6323-6331
63. Hashimoto S, Pittet JF, Hong K, et al. Depletion of alveolar macrophages decreases neutrophil chemotaxis to Pseudomonas airspace infections. Am J Physiol 1996;270:L819-L828
64. Broug-Holub E, Toews GB, van Iwaarden JF, et al. Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival. Infect Immun 1997;65:1139-1146
65. Heagy W, Hansen W, Nieman K, et al. Impaired ex vivo lipopolysaccharide-stimulated whole blood tumor necrosis factor production may identify "septic" intensive care unit patients. Shock 2000;14: 271-276; discussion 276-277
66. Nomura F, Akashi S, Sakao Y, et al. Endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol 2000;164:3476-3479
67. Sato S, Nomura F, Kawai T, et al. Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR-4-mediated signaling pathways. J Immunol 2000;165:7096-7101
68. Fahmi H, Chaby R. Desensitization of macrophages to endotoxin effects is not correlated with a down-regulation of lipopolysaccharide-binding sites. Cell Immunol 1993;150:219-229
69. Jacinto R, Hartung T, McCall C, Li L. Lipopolysaccharide- and lipoteichoic acid-induced tolerance and cross-tolerance: distinct alterations in il-1 receptor-associated kinase. J Immunol 2002;168:6136-6141
70. Shennib H, Chu-Jeng R, Mulder D, Richards G, Prentis J. Pulmonary bacterial clearance and alveolar macrophage function in septic shock lung. Am Rev Respir Dis 1984;130:444-449
71. Jacobs RF, Kiel DP, Balk RA. Alveolar macrophage function in a canine model of endotoxin-induced lung injury. Am Rev Respir Dis 1986;134:745-751
72. Jacobs RF, Dorsey DR, Tryka AF, Tabor DR. Pulmonary macrophage antimicrobial activity in canine endotoxin shock and lung injury. Exp Lung Res 1988;14:359-374
73. Tabor D, Kiel D, Jacobs R. Receptor-mediated ingestion responses by lung macrophages from a canine model of ARDS. J Leukoc Biol 1987;41:539-543
74. Mason CM, Dobard E, Summer WR, Nelson S. Intraportal lipopolysaccharide suppresses pulmonary antibacterial defense mechanisms. J Infect Dis 1997;176:1293-1302
75. Christman JW, Petras SF, Hacker M, Absher PM, Davis GS. Alveolar macrophage function is selectively altered after endotoxemia in rats. Infect Immun 1988;56:1254-1259
76. Frevert CW, Warner AE, Weller E, Brain JD. The effect of endotoxin on in vivo rat alveolar macrophage phagocytosis. Exp Lung Res 1998;24:745-758
77. Harris SE, Nelson S, Astry CL, Bainton BG, Summer WR. Endotoxin-induced suppression of pulmonary antibacterial defenses against Staphylococcus aureus. Am Rev Respir Dis 1988;138:1439-1443
78. Goya T, Abe M, Shimura H, Torisu M. Characteristics of alveolar macrophages in experimental septic lung. J Leukoc Biol 1992;52:236-243
79. Coffey MJ, Phare SM, Peters-Golden M. Prolonged exposure to lipopolysaccharide inhibits macrophage 5-lipoxygenase metabolism via induction of nitric oxide synthesis. J Immunol 2000;165:3592-3598
80. Toews GB, Gross GN, Pierce AK. The relationship of inoculum size to lung bacterial clearance and phagocytic cell response in mice. Am Rev Respir Dis 1979;120:559-566
81. Rehm SR, Gross GN, Pierce AK. Early bacterial clearance from murine lungs. Species-dependent phagocyte response. J Clin Invest 1980;66:194-199
82. Onofrio JM, Toews GB, Lipscomb MF, Pierce AK. Granulocyte-alveolar-macrophage interaction in the pulmonary clearance of Staphylococcus aureus. Am Rev Respir Dis 1983;127:335-341
83. White JC, Nelson S, Winkelstien J, Booth F, Jakab G. Impairment of antibacterial defense mechanisms of the lung by extrapulmonary infection. J Infect Dis 1986;153:202-208
84. Nelson S, Chidiac C, Bagby G, Summer WR. Endotoxin-induced suppression of lung host defenses. J Med 1990;21:85-103
85. Nelson S, Mason C, Bagby G, Nakamura C, Summer W. Lipopolysaccharide-induced inhibition of intrapulmonary tumor necrosis factor and lung antibacterial defenses. Am Rev Respir Dis 1990;141:A512
86. Frevert CW, Warner AE, Kobzik L. Defective pulmonary recruitment of neutrophils in a rat model of endotoxemia. Am J Respir Cell Mol Biol 1994;11:716-723
87. Hirano S. Migratory responses of PMN after intraperitoneal and intratracheal administration of lipopolysaccharide. Am J Physiol 1996;270(5 Pt 1):L836-L845
88. Wagner JG, Harkema JR, Roth RA. Pulmonary leukostasis and the inhibition of airway neutrophil recruitment are early events in the endotoxemic rat. Shock 2002;17:151-158
89. Hartiala KT, Langlois L, Goldstein IM, Rosenbaum JT. Endotoxin-induced selective dysfunction of rabbit polymorphonuclear leukocytes in response to endogenous chemotactic factors. Infect Immun 1985;50:527-533
90. Wagner JG, Driscoll KE, Roth RA. Inhibition of pulmonary neutrophil trafficking during endotoxemia is dependent on the stimulus for migration. Am J Respir Cell Mol Biol 1999;20:769-776
91. Bignold LP, Rogers SD, Siaw TM, Bahnisch J. Inhibition of chemotaxis of neutrophil leukocytes to interleukin-8 by endotoxins of various bacteria. Infect Immun 1991;59:4255-4258
92. Gimbrone MA Jr, Obin MS, Brock AF, et al. Endothelial interleukin-8: a novel inhibitor of leukocyte-endothelial interactions. Science 1989;246:1601-1603
93. Hechtman DH, Cybulsky MI, Fuchs HJ, Baker JB, Gimbrone MJ. Intravascular IL-8: inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. J Immunol 1991;147:883-892
94. Sano H, Sata T, Nanri H, Ikeda M, Shigematsu A. Thioredoxin is associated with endotoxin tolerance in mice. Crit Care Med 2002;30:190-194
95. Nakamura H, Herzenberg LA, Bai J, et al. Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc Natl Acad Sci USA 2001;98:15143-15148
96. Blackwell TS, Lancaster LH, Blackwell TR, Venkatakrishnan A, Christman JW. Chemotactic gradients predict neutrophilic alveolitis in endotoxin-treated rats. Am J Respir Crit Care Med 1999;159:1644-1652
97. Duffy AJ, Nolan B, Sheth K, et al. Inhibition of alveolar neutrophil immigration in endotoxemia is macrophage inflammatory protein 2 independent. J Surg Res 2000;90:51-57
98. Ferri LE, Swartz D, Christou NV. Soluble L-selectin at levels present in septic patients diminishes leukocyte-endothelial cell interactions in mice in vivo: a mechanism for decreased leukocyte delivery to remote sites in sepsis. Crit Care Med 2001;29:117-122
99. Benjamim CF, Ferreira SH, Cunha FQ. Role of nitric oxide in the failure of neutrophil migration in sepsis. J Infect Dis 2000;182:214-223
100. Benjamim CF, Silva JS, Fortes ZB, et al. Inhibition of leukocyte rolling by nitric oxide during sepsis leads to reduced migration of active microbicidal neutrophils. Infect Immun 2002;70:3602-3610
101. Crosara-Alberto DP, Darini AL, Inoue RY, et al. Involvement of NO in the failure of neutrophil migration in sepsis induced by Staphylococcus aureus. Br J Pharmacol 2002;136:645-658
102. Matute-Bello G, Frevert CW, Kajikawa O, et al. Septic shock and acute lung injury in rabbits with peritonitis, failure of the neutrophil response to localized infection. Am J Respir Crit Care Med 2001;163:234-243
103. Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999;27:1230-1251
104. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol 2002;168:2493-2500
105. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci USA 1999;96:14541-14546
106. Hotchkiss RS, Chang KC, Swanson PE, et al. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 2000;1:496-501
107. Tinsley KW, Grayson MH, Swanson PE, et al. Sepsis induces apoptosis and profound depletion of splenic interdigitating and follicular dendritic cells. J Immunol 2003;171:909-914
108. Fadok VA, Bratton DL, Konowal A, et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998;101:890-898
109. Fadok VA, Bratton DL, Henson PM. Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences. J Clin Invest 2001;108:957-962
110. Fadok VA, Chimini G. The phagocytosis of apoptotic cells. Semin Immunol 2001;13:365-372
111. Hotchkiss RS, Chang KC, Grayson MH, et al. Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis. Proc Natl Acad Sci USA 2003;100:6724-6729
112. Martin TR. Recognition of bacterial endotoxin in the lungs. Am J Respir Cell Mol Biol 2000;23:128-132
113. Fan MH, Klein RD, Steinstraesser L, et al. An essential role for lipopolysaccharide-binding protein in pulmonary innate immune responses. Shock 2002;18:248-254
114. Le Roy D, Di Padova F, Adachi Y, et al. Critical role of lipopolysaccharide-binding protein and CD14 in immune responses against gram-negative bacteria. J Immunol 2001;167:2759-2765
115. McCormack FX, Whitsett JA. The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J Clin Invest 2002;109:707-712
116. Sano H, Chiba H, Iwaki D, et al. Surfactant proteins A and D bind CD14 by different mechanisms. J Biol Chem 2000;275:22442-22451
117. Guillot L, Balloy V, McCormack FX, et al. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol 2002;168:5989-5992
118. Wright JR. Immunomodulatory functions of surfactant. Physiol Rev 1997;77:931-962
119. Awasthi S, Coalson JJ, Yoder BA, Crouch E, King RJ. Deficiencies in lung surfactant proteins A and D are associated with lung infection in very premature neonatal baboons. Am J Respir Crit Care Med 2001;163:389-397
120. LeVine AM, Kurak KE, Bruno MD, et al. Surfactant protein-A-deficient mice are susceptible to Pseudomonas aeruginosa infection. Am J Respir Cell Mol Biol 1998;19:700-708
121. LeVine AM, Kurak KE, Wright JR, et al. Surfactant protein-A binds group B streptococcus enhancing phagocytosis and clearance from lungs of surfactant protein-A-deficient mice. Am J Respir Cell Mol Biol 1999;20:279-286
122. Chabot S, Salez L, McCormack FX, Touqui L, Chignard M. Surfactant protein A inhibits lipopolysaccharide-induced in vivo production of interleukin-10 by mononuclear phagocytes during lung inflammation. Am J Respir Cell Mol Biol 2003;28:347-353
123. Abraham E. Neutrophils and acute lung injury. Crit Care Med 2003;31(suppl 4):S195-199
124. LeVine AM, Whitsett JA, Gwozdz JA, et al. Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. J Immunol 2000;165:3934-3940
125. Bufler P, Schmidt B, Schikor D, et al. Surfactant protein A and D differently regulate the immune response to nonmucoid Pseudomonas aeruginosa and its lipopolysaccharide. Am J Respir Cell Mol Biol 2003;28:249-256
126. Augusto LA, Synguelakis M, Johansson J, et al. Interaction of pulmonary surfactant protein C with CD14 and lipopolysaccharide. Infect Immun 2003;71:61-67
127. Augusto LA, Synguelakis M, Espinassous Q, et al. Cellular anti-endotoxin activities of lung surfactant protein C in lipid vesicles. Am J Respir Crit Care Med 2003;168:335-341
128. Wang SC, Klein RD, Wahl WL, et al. Tissue coexpression of LBP and CD14 mRNA in a mouse model of sepsis. J Surg Res 1998;76:67-73
129. Malloy J, Mccaig L, Veldhuizen R, et al. Alterations of the endogenous surfactant system in septic adult rats. Am J Respir Crit Care Med 1997;156:617-623
130. Herbein JF, Wright JR. Enhanced clearance of surfactant protein D during LPS-induced acute inflammation in rat lung. Am J Physiol Lung Cell Mol Physiol 2001;281:L268-L277
131. Martin TR. Lung Cytokines and ARDS. Chest 1999;116:2S-8S
132. Martin TR, Goodman RB. The role of chemokines in the pathophysiology of the acute respiratory distress syndrome (ARDS). In: Hebert CA, ed. Chemokines in Disease: Biology and Clinical Research. Totowa, NJ: Humana; 1999:81-110
133. Martin TR, Matute-Bello G, Skerrett SJ, Frevert CW. Extrapulmonary sepsis and cytokines in lung injury and defenses. In: Nelson S, Martin TR, eds. Cytokines in Pulmonary Disease: Infection and Inflammation. New York: Marcel Dekker; 2000:403-458
134. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334-1349